Results. The unadjusted odds ratio for moderatehigh prescription frequency of opioids for individuals who had previously used benzodiazepines was 7.7 (95% confidence interval 5.6-10.5) as compared with previous nonusers. After adjustment for musculoskeletal pain, alcohol, smoking habits, and socioeconomic variables, the odds ratio was lowered to 3.1 (2.1-4.6). The analysis of the effect of benzodiazepines and chronic pain individually and in combination suggest that use of benzodiazepines is an even stronger predictor of later opioid use than self-reported chronic pain.
Introduction
In the last few decades, opioids have been considered useful treatment option not only for cancer related and severe acute pain, but also to some extent for chronic nonmalignant pain. Guidelines recommend the use of long acting opioids, while suggesting that short acting opioids should be avoided [1] [2] [3] [4] [5] [6] . However, the beneficial effect of long lasting opioid treatment has been questioned [3] [4] [5] [6] . Opioids should be avoided in patients using other addictive drugs such as benzodiazepines, because this may increase the potential for problematic use or abuse. There are no recommendations concerning the use of weak opioids, although these are by far the most widely used opioids in Europe [7] [8] [9] .
Chronic nonmalignant pain lasting 6 months or more affects between 12% and 30% of the adult western population [8, 10] . Tissue damage is often followed by pain. How pain is perceived is, however, not only related to the extent of the damage, but also to other more subjective factors such as personality traits and mental state. This is even more so for musculoskeletal pain, which is not related to malignant disease or trauma. The most commonly reported locations for pain are in the back, knee, neck, hand, or leg. It has been documented that pain has an impact on employment status, family relationships and emotional status [8, 10] . Breivik et al. documented that more than 20% of pain patients had been diagnosed with depression [8] . The likelihood of an individual taking pain medication may also be influenced by personality and emotional characteristics.
The most commonly prescribed medicines for pain are nonsteroid anti-inflammatory drugs (NSAIDs) and weak opioids. Use of opioids for chronic noncancer pain is increasing in many countries [8, 11, 12] . A Danish study, based on data from 2000, indicated that 9% of those reporting chronic nonmalignant pain used weak opioids regularly or continuously [13] . Approximately 3% of the US general population without cancer used opioids regularly for a month or more per year [14] . However, the epidemiology of opioid-taking behaviors of noncancer patients has not been fully investigated [15] .
An association between the use of analgesics and of anxiolytics or hypnotics has been suggested in crosssectional studies [7, 16] . In an earlier prospective study, we have shown that earlier use of benzodiazepines was associated with increased prescription of opioids 20 years later in all those individuals who also consumed alcohol, even after controlling for several potential confounders. Only a weak association was observed between earlier use of benzodiazepines and later use of NSAIDs for the treatment of pain [17] . However, we were unable to determine whether this study result was related to different levels of pain in the two groups.
In current study, the association between the use of benzodiazepines and later opioid use was investigated in different age groups, adjusting for musculoskeletal pain. Data from the Norwegian health surveys were linked to data from a prescription database 4-7 years later. We excluded patients with cancer pain and restricted the study to participants who reported no use of opioids at baseline. We adjusted for a series of other factors that may have influenced the later use of opioids.
Materials and Methods

Health Survey-Information on Independent Variables
Data from population based surveys conducted in 2000-2001 in the three Norwegian counties Oslo, Oppland and Hedmark are included in this study [18] . These three counties cover both rural and urban regions. The surveys are part of Cohort of Norway (CONOR) [19] . The number of individuals invited and the number of participants in CONOR, as well as the procedures used, have been published elsewhere [19] . All subjects in selected age cohorts were invited to participate in the respective surveys. At the time of investigation, the subjects were aged 40-41, 45-46, and 59-61 years. In these age cohorts, 21,802 men and 21,451 women were invited. Of these, 9,386 men (43.1%) and 11,244 women (52.4%) participated and agreed to the storage of blood samples and data for research purposes and agreed to have their data linked to other health registers ( Figure 1 ). One hundred twenty-two men and 124 women who died or emigrated before January 1, 2004 were excluded from the analyses. In a second step, we removed all those whose drugs were reimbursed for the treatment of cancer ( Figure 1 ).
The participants in the health survey completed a selfadministered questionnaire covering drug use, history of cardiovascular disease and diabetes, and different lifestyle Figure 1 Flow chart for the study population. Health surveys in Oslo, Oppland and Hedmark (2000-2001) . *Subsample of the study population who had answered a second questionnaire including question regarding chronic pain. BZD = benzodiazepine. habits such as alcohol use, smoking, and physical activity (Table 1) . Drug use questions consisted of specific questions related to the frequency of use of different drug categories during the previous 4 weeks, followed by an open question on drug trade names [18] . It was possible to register up to 10 different trade names in the selfadministered questionnaire. Only 0.1% of attendees in the surveys reported ten different trade names, suggesting that very few, if any, were using more. The questionnaire included a specific question on the use of analgesics ("pain medicine" in questionnaire), anxiolytics ("tranquillizers") or hypnotics ("sleeping medicine") on prescription (Table 1 ) [18] . Validity on drug use questions are described earlier [20] . The participants who answered that they used anxiolytics (whether daily, weekly, or less than weekly) during the previous month in the specific question and/or who wrote trade names of benzodiazepines in the open question, are referred to below as "benzodiazepine users". We chose to examine the effect of only benzodiazepines on later use of opioids, not the benzodiazepine-like zopiclone and zolpidem because they have well known negative effects that interfere with people's daily functioning [21] . Opioid users were defined as individuals who wrote in "open" question down the trade names of opioids used during the previous month. Regarding alcohol use, participants were divided in three categories: nondrinkers, alcohol use Յ3 times a week and alcohol use Ն4 times a week. The questionnaire included questions about the location, intensity and duration of musculoskeletal pain [18] . Participants were divided in three groups: no painful areas; some/very troubled in one to two painful areas or some/very troubled in three to six areas. Physically active Have you, during the past year, suffered from pain and/or stiffness in muscles and joints that has lasted for at least 3 months?
Yes; no individuals were those doing exercise for at least 3 hours a week. A physical examination comprised measurements of weight, height, and blood pressure. In addition, a second questionnaire handed out at screening included a question regarding chronic pain: "Have you, during the past year, suffered from pain and /or stiffness in muscles and joints that has lasted for at least 3 months?"
A total of 8,152 men and 9,436 women were defined as nonusers of opioids in 2000-2001 according to the definition ( Figure 1 ). Of these, we had information from 7,991 men and 9,083 women on their use/nonuse of benzodiazepines at the baseline according to the definitions above. These individuals constitute our study population and were followed up for subsequent prescription of opioids in 2004-2007 ( Figure 1 ).
In parallel, in the subgroup who had responded to the second questionnaire including a question regarding chronic pain, 6,425 men and 7,487 women were followed with respect to subsequent prescription of opioids in 2004-2007.
Information about marital status was retrieved from the Norwegian Person Registry.
Norwegian Prescription Database (NorPD)-Information on Dependent Variables
Prescription data about opioids in 2004-2007 were drawn from the NorPD, which covers the entire nation (4.7 million inhabitants). From January 1 2004, all pharmacies in Norway have been legally obliged to send in electronic data on all prescriptions. NorPD contains information on all individuals living outside institutions who have received prescription drugs dispensed at pharmacies [22] . All prescriptions from ambulatory care, whether publicly reimbursed or not, are stored in the database. The drugs are classified according to the Anatomical Therapeutic Chemical (ATC) classification [23] . The data collected for our study were patient unique identifying number (encrypted), sex, age, the date the drug was dispensed, and drug information (brand name, package size, number of packages, ATC-code, defined daily dose [DDDs]). The reimbursement code is also recorded and this functions as a proxy for diagnosis.
The opioids were defined by the ATC code N02A in the ATC-classification system [23] . The weak opioids used in Norway are codeine, dextropropoxyphene and tramadol, whereas the remaining opioids (ketobemidone, morphine, fentanyl, buprenorphine, hydromorphone, oxycodone, pethidine, fentanyl, pentazocine) are categorized as strong opioids.
For each prescription number of DDD's dispensed are recorded. A DDD is defined as the assumed average maintenance dose per day for a drug used on its main indication in adults. DDD's for opioids are described earlier [24] . Data from the health surveys and NorPD were linked using the unique 11-digit identification number, assigned to all individuals living in Norway. The record-linkage was approved by the Norwegian Data Inspectorate.
Statistics
Chi-square test was used to assess equality of proportions across the groups of drug use. Odds ratio (OR) with 95% confidence intervals (CI) were estimated by logistic regression. All analyses were carried out using SPSS 14.0 for Windows (SPSS Inc., Chicago, IL, USA). The level of significance was set to P < 0.05. For the fit of the logistic regression model the Hosmer-Lemeshow test was applied [25] . We ran logistic regression on strata with and without chronic pain. The logistic regression model is multiplicative. Rothman has argued that interaction on an addictive scale better reflects biologic interaction [26] . An additive model is also more relevant from the view of public health as it takes the absolute level of risk into account. By defining a logistic regression model including the individual effects of two exposures and their joint effect relative to the group not exposed to any of the two, it is possible to assess additive interaction [26, 27] . Relative excess risk due to interaction (RERI) with 95% confidence interval is presented [27, 28] . If the confidence interval does not cover 0, there is a significant additive interaction (P < 0.05).
Results
The characteristics of the study population are shown in Table 2 . The proportion of benzodiazepine users was higher for women (N = 479; 5.3%) than for men (N = 289; 3.6%). There was a higher prevalence of nondrinkers, current daily smokers and physically inactive people among users of benzodiazepines. There was also a higher prevalence of unmarried individuals, of people receiving disability pensions and people reporting history of cardiovascular disease among the users of benzodiazepines. Benzodiazepine users were more likely than nonusers to report musculoskeletal pain in three or more locations in the body.
The incidence of moderate to high prescription frequency of opioids 4-7 years after baseline measurements was higher for men and women with a history of using benzodiazepines (Table 3) . Weak opioids were dominant. Codeine combinations made up 79% of all these prescriptions followed by tramadol (12%) (data not shown). Opioids in combination with benzodiazepines were more commonly dispensed during 2004-2007 to those who reported use of a benzodiazepine at baseline in 2000-2001 than those who did not, for both men and women (Table 3 ).
The unadjusted OR for later being a moderate to high user of prescription opioids was 7.7 for individuals who used benzodiazepines at the baseline, compared with nonusers (Table 4) . After adjustment for reported baseline musculoskeletal pain, lifestyle, socio-economic variables the OR was reduced to 3.1. People who were current daily smokers, who were on disability pension or who reported three or more types of musculoskeletal pain had an adjusted OR of 2.5 or higher. Disability pension and the Unmarried people had 50% higher odds than married people of becoming a moderate to high user of opioids. There was no effect of alcohol use in the overall analysis. The adjusted model seems to fit well as the HosmerLemeshow goodness of fit test was 6.0 with P value 0.65. Chronic pain was included in analyses of a subsample who had answered a supplementary questionnaire at screening. Higher proportion of women (41.8%) than men (32.2%) reported chronic pain. Among people reporting no use of benzodiazpines at baseline the incidence of moderate to high frequency of opioid prescription 2004-2007 was only 0.6% in people reporting no chronic pain, increasing to 1.6% in people reporting chronic pain (Table 5) . Thus the prevalence difference or excess prevalence due to chronic pain is 1%. In people reporting no chronic pain, the prevalence increased from 0.6% in nonusers of benzodiazepines to 4.1% in users. The prevalence difference or excess prevalence due to use of benzodiazepines is 3.5%.The prevalence is particularly high, 10%, in people reporting both use of benzodiazepines and chronic pain at baseline. The excess rate due to interaction is 4.9%. This means that the combined effect of use of benzodiazepines and chronic pain is 4.9 percentage points greater than the sum of the individual effects (10 -0.6 -[3.5
. The corresponding RERI is 9.7% (18.6 -2.8 -[7.1 -1.0] = 9.7) with 95% CI 1.4-17.9. This means that there is a significant positive interaction on the additive scale. The odds ratio for opioid use by chronic pain only was almost the same in unadjusted (OR = 2.8) and adjusted analyses (OR = 2.3), whereas the odds ratio for benzodiazepines only, and in combination with chronic pain, was markedly reduced after adjustment, from 7.1 to 4.4 and from 18.6 to 8.0, respectively (Table 5 ). There was no significant additive interaction in the adjusted model (RERI = 2.4 with 95% CI -2.0-6.9). The Hosmer-Lemeshow test statistic was 9.0 with P-value 0.35 suggesting adequate fit. In analyses of people with and without chronic pain separately adjusted odds ratios for opioid use by use of benzodiazepines were 4.8 (95% CI 2.3-10.2) in people with no chronic pain and 3.6 (95% CI 2.2-6.1) in people with chronic pain (not shown). Thus, there was a significant effect of use of benzodiazepines in both groups.
Discussion
In this prospective study, the use of benzodiazepines was associated with a higher prescription frequency of opioids 4-7 years later. The study suggests that the probability of being prescribed opioids is associated with previous use of benzodiazepines, independent of the patients' reported musculoskeletal pain/chronic pain.
The prevalence of moderate to high prescription frequency of opioids was particularly high among individuals reporting both chronic pain and use of benzodiazepines at baseline. Before adjustment for confounders there was a significant additive interaction.
The analyses of the effect of benzodiazepines and chronic pain individually and in combination suggest that use of benzodiazepines is an even stronger predictor of later opioid use than self-reported chronic pain. The association with benzodiazepines was, however, markedly reduced after adjustment. Benzodiazepine users had a Table 5 Prevalence (%) and odds ratio (ORs) with confidence intervals (CI) of receiving a moderate/high prescription frequency of opioids higher prevalence of disability pension, cardiovascular disease and reported musculoskeletal pain than nonusers. Thus, chronic illness at baseline may partly explain the association between use of benzodiazepines and later use of opioids. There was, however, still a substantial effect of benzodiazepines after adjustment, suggesting an independent effect. Probably there is a complex relationship between the independent variables and the use of opioids. Whatever the mechanism, we can, however, conclude that benzodiazepine use is an important predictor of later use of opioids.
This study confirms results from our earlier study on the association between use of benzodiazepines and moderate to high prescription frequency of opioids [17] . In the current study, we had a shorter observation period, 4-6 years compared with 20 in the earlier study. We were also able to adjust for reported symptoms of musculoskeletal pain. Different ages of participants in the studies should also to be mentioned. Other studies on opioid use and risk factors have been cross sectional and often based on self reported use of medicine. We are not aware of other longitudinal analyses in the general population that were able to adjust for risk factors that were present before opioid treatment was started.
As expected, self-reported musculoskeletal symptoms or chronic pain were important predictors of subsequent moderate to high opioid use. A cross-sectional population study from Denmark found a higher proportion of opioid users in groups reporting pain [13] . In our study, receiving disability pension and being a current daily smoker were strong predictors for later use of moderate-high amount of opioids. This is in agreement with what has been documented in an earlier cross-sectional study [13] .
One-year period prevalence shows that 9.7% of the Norwegian population was dispensed at least one opioid analgesic for noncancer related pain in 2007 [24] . Among persons with noncancer pain 77% received only one dispension per year and 1-2 percentiles received 12 and more prescription during the period of 4 years [24] . Use of strong opioids is less common among noncancer patients. The prevalence of weak opioids was 9.3% compared with 0.3% for strong opioids [29] . In Norway, there is a high consumption of short-acting codeine (12.9 DDD/ 1,000/day) and more than 70% of the opioids in our study were codeine compounds. Other weak opioids for the treatment of moderate pain are tramadol and dextropropoxyphene, but they are less frequently used in Norway [29] . Cross sectional study on codeine use in Norway in 2006 showed that codeine use in the entire Norwegian population was mainly sporadic, but that a relatively large sub-group of users were dispensed repeated prescriptions of the drug in combination with other potential drugs of abuse such as benzodiazepines and carisoprodol [7] .
The use of benzodiazepines at baseline could influence the decision to start opioid medication in different ways. The use of benzodiazepines could be regarded as a proxy of psychiatric disorders. Studies have shown that psychiatric patients are more prone to pain [30] and that common psychiatric disorders (depression and anxiety) may predict initiation and continuation of opioid use in patients with chronic pain [31] . For benzodiazepines, there is also a concern about long-term use and addiction problems. Long-term therapeutic use of benzodiazepines in the population is quite common [32] [33] [34] . It is also common to use benzodiazepines and opioids in combination [7, 35] . This combined use is regarded as particularly problematic for addiction potential.
This is a prospective study, using an endpoint recorded in a national register. This design limits recall bias. However, the end point is based on dispensed drugs, and we do not know if the drugs were actually taken. Furthermore, this study included data on drug use from ambulatory care only, as the NorPD does not include person-specific data from inpatient care. Because our study has a maximum age for participants of less than 67 years, this potential bias is likely to be minimal. Although many potential confounders were registered at baseline, it is not possible to take all confounders into account. For example, we do not know the indication for the prescription of opioid analgesics. It could also be argued that the participants' habits may have changed since the screening took place 4-7 years before the endpoint was recorded. Change in risk factors during follow-up is a problem inherent in all follow-up studies with only baseline information. Also, the information on drug use during the 4 weeks at baseline was self-reported. Underreporting of both benzodiazepines and opioids at baseline would be likely to bias the odds ratio estimates towards the null.
The attendance rates were 43% in men and 52% in women. Further losses resulted from missing data on benzodiazepine and/or opioid use at baseline. We investigated selection bias by comparing dispensing of benzodiazepines and/or opioids in the period 2004-2007 in the attendees, responders (attendees who answered the questions about opioids and benzodiazepines at baseline), and nonresponders with the general population in the same age groups. The period prevalence of benzodiazepines and/or opioids was slightly lower in the attendees than in the general population. The prevalence was further slightly lower in responders. The prevalence was generally somewhat higher in nonresponders than in responders. It is a more likely nonresponse from the most frequent drug users or even drug abusers. Even if the prevalence of drug use is lower among attendees there is not necessarily a selection bias in the association between use of benzodiazepines and opioids. To study possible selection bias we have analyzed the association between use of benzodiazepines and use of opioids in the prescription database in the period 2004-2007 in attendees, responders, nonresponders and the general population in the same age groups. The percentage of users of benzodiazepines (at least one prescription dispensed in 2004-2007) who also used opioids during the period was similar in all groups and similar to the general population, slightly above 50%. This indicates limited bias in the reported association between use of benzodiazepines at baseline and later use of opioids.
A dose-response relationship between the frequency of benzodiazepine drug use and total mortality has been reported [16] . Excluding individuals who died between the baseline and the establishment of NorPD would probably affect the estimates of association. As users of benzodiazepines have higher mortality rates than nonusers, the bias would be towards the null. We chose to examine the effect of benzodiazepines on later use of opioids, excluding the benzodiazepine-like zopiclone and zolpidem, which are the most commonly used hypnotics [29] . Although recent literature suggests an addictive potential for these drugs similar to that of traditional benzodiazepines [36] , these substances are now more commonly used as first-choice hypnotics. We wanted to restrict our analysis to the traditional benzodiazepines, which have well known abuse potential.
Opioids may cause cognitive and psychomotor impairment and are potential drugs of abuse [11, 37, 38] . However, a total of twelve or more prescriptions of opioids over 4 years does not necessarily indicate a problematic use of opioids, and does not indicate abuse or addictive use per se. The concomitant use of benzodiazepines and opioids in those patients who do not report musculoskeletal symptoms or chronic pain warrants further investigation.
Finally, there are no randomized controlled trials on longterm effects and consequences of opioid use in noncancer patients [39] . It could be argued that opioids have benefits in the short term, but in the long run may cause harm. It is therefore important to investigate predictors for moderate to high or long term use of opioids in noncancer patients [15] . Before starting pain treatment with opioids, clinicians should take into consideration the possibility of substance abuse or mental health disorders. A central issue when prescribing opioids for chronic noncancer pain is to balance the risk of problematic use of these drugs with the benefits of pain relief. Our study suggests that earlier use of benzodiazepines may predict repeated use of opioids.
